Medarex achieves milestone
Medarex has achieved a significant milestone under its 1999 agreement with Amgen Inc. The achievement of this milestone will trigger an undisclosed payment to Medarex.
Medarex has achieved a significant milestone under its 1999 agreement with Amgen Inc. The achievement of this milestone will trigger an undisclosed payment to Medarex.
'We are pleased to add Amgen to the growing list of companies that have advanced the development of antibodies generated using the Medarex technology,' said Donald L. Drakeman, President and CEO of Medarex. Medarex is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating diseases.
Medarex's UltiMAb Human Antibody Development System is a combination of human antibody technologies that Medarex believes enables the rapid creation and development of fully human antibodies to a wide range of potential disease targets for therapeutic antibody products, including products for the treatment of cancer, inflammation, autoimmune and infectious diseases.
Medarex's product pipeline is based on a variety of therapeutic antibody products developed through the use of its UltiMAb technology. Medarex creates and develops fully human antibodies for itself and others.